Crossmark

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

Crossref DOI link: https://doi.org/10.1007/s10147-015-0943-z

Published Online: 2016-01-08

Published Print: 2016-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Miyamoto, Yuji

Tsuji, Akihito

Tanioka, Hiroaki

Maekawa, Soichiro

Kawanaka, Hirofumi

Kitazono, Masaki

Oki, Eiji

Emi, Yasunori

Murakami, Hidetsugu

Ogata, Yutaka

Saeki, Hiroshi

Shimokawa, Mototsugu

Natsugoe, Shoji

Akagi, Yoshito

Baba, Hideo

Maehara, Yoshihiko
License Information

Text and Data Mining valid from 2016-01-08

Updates are available Correction dated 2017-11-14

Click to view Correction: https://doi.org/10.1007/s10147-017-1212-0